Visceral and subcutaneous fat in patients treated with olanzapine: a case series

Objectives: - We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome. - Methods: - Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gilles, Maria (VerfasserIn) , Hentschel, Frank (VerfasserIn) , Paslakis, Georgios (VerfasserIn) , Glahn, Eva Valerie (VerfasserIn) , Lederbogen, Florian (VerfasserIn) , Deuschle, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2010
In: Clinical neuropharmacology
Year: 2010, Jahrgang: 33, Heft: 5, Pages: 248-249
ISSN:1537-162X
DOI:10.1097/WNF.0b013e3181f0ec33
Online-Zugang:Verlag, Volltext: https://doi.org/10.1097/WNF.0b013e3181f0ec33
Verlag: https://journals.lww.com/clinicalneuropharm/Abstract/2010/09000/Visceral_and_Subcutaneous_Fat_in_Patients_Treated.7.aspx
Volltext
Verfasserangaben:Maria Gilles, Frank Hentschel, Georgios Paslakis, Valerie Glahn, Florian Lederbogen, Michael Deuschle

MARC

LEADER 00000caa a2200000 c 4500
001 1735645524
003 DE-627
005 20240407193346.0
007 cr uuu---uuuuu
008 201015s2010 xx |||||o 00| ||eng c
024 7 |a 10.1097/WNF.0b013e3181f0ec33  |2 doi 
035 |a (DE-627)1735645524 
035 |a (DE-599)KXP1735645524 
035 |a (OCoLC)1341371420 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Gilles, Maria  |d 1972-  |e VerfasserIn  |0 (DE-588)137091877  |0 (DE-627)589925148  |0 (DE-576)302138528  |4 aut 
245 1 0 |a Visceral and subcutaneous fat in patients treated with olanzapine  |b a case series  |c Maria Gilles, Frank Hentschel, Georgios Paslakis, Valerie Glahn, Florian Lederbogen, Michael Deuschle 
264 1 |c 2010 
300 |a 2 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 15.10.2020 
520 |a Objectives: - We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome. - Methods: - Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glucose, and lipids in an unselected population of 14 schizophrenic patients. - Results: - We found a 6-week olanzapine treatment to be related to increased body mass index and proportion of total fat at the level of the fourth vertebral body. - Conclusions: - On the basis of these findings, we conclude that weight gain after a 6-week olanzapine treatment is partly attributable to increased visceral fat and may thus contribute to metabolic syndrome. 
700 1 |a Hentschel, Frank  |e VerfasserIn  |0 (DE-588)1110919611  |0 (DE-627)865216525  |0 (DE-576)475836138  |4 aut 
700 1 |a Paslakis, Georgios  |d 1978-  |e VerfasserIn  |0 (DE-588)134244591  |0 (DE-627)565613367  |0 (DE-576)300399472  |4 aut 
700 1 |a Glahn, Eva Valerie  |d 1981-  |e VerfasserIn  |0 (DE-588)137451865  |0 (DE-627)695824392  |0 (DE-576)303155434  |4 aut 
700 1 |a Lederbogen, Florian  |e VerfasserIn  |0 (DE-588)1029138915  |0 (DE-627)732485444  |0 (DE-576)376591692  |4 aut 
700 1 |a Deuschle, Michael  |d 1963-  |e VerfasserIn  |0 (DE-588)1029068801  |0 (DE-627)732393086  |0 (DE-576)376532408  |4 aut 
773 0 8 |i Enthalten in  |t Clinical neuropharmacology  |d Philadelphia, Pa. : Lippincott Williams & Wilkins, 1976  |g 33(2010), 5, Seite 248-249  |h Online-Ressource  |w (DE-627)330078143  |w (DE-600)2048796-4  |w (DE-576)09618888X  |x 1537-162X  |7 nnas  |a Visceral and subcutaneous fat in patients treated with olanzapine a case series 
773 1 8 |g volume:33  |g year:2010  |g number:5  |g pages:248-249  |g extent:2  |a Visceral and subcutaneous fat in patients treated with olanzapine a case series 
856 4 0 |u https://doi.org/10.1097/WNF.0b013e3181f0ec33  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://journals.lww.com/clinicalneuropharm/Abstract/2010/09000/Visceral_and_Subcutaneous_Fat_in_Patients_Treated.7.aspx  |x Verlag 
951 |a AR 
992 |a 20201015 
994 |a 2010 
998 |g 1029068801  |a Deuschle, Michael  |m 1029068801:Deuschle, Michael  |d 60000  |e 60000PD1029068801  |k 0/60000/  |p 6  |y j 
998 |g 1029138915  |a Lederbogen, Florian  |m 1029138915:Lederbogen, Florian  |d 60000  |e 60000PL1029138915  |k 0/60000/  |p 5 
998 |g 137451865  |a Glahn, Eva Valerie  |m 137451865:Glahn, Eva Valerie  |p 4 
998 |g 134244591  |a Paslakis, Georgios  |m 134244591:Paslakis, Georgios  |p 3 
998 |g 1110919611  |a Hentschel, Frank  |m 1110919611:Hentschel, Frank  |d 60000  |e 60000PH1110919611  |k 0/60000/  |p 2 
998 |g 137091877  |a Gilles, Maria  |m 137091877:Gilles, Maria  |d 60000  |e 60000PG137091877  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1735645524  |e 3780109174 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"family":"Gilles","given":"Maria","role":"aut","display":"Gilles, Maria"},{"role":"aut","given":"Frank","display":"Hentschel, Frank","family":"Hentschel"},{"given":"Georgios","role":"aut","display":"Paslakis, Georgios","family":"Paslakis"},{"given":"Eva Valerie","role":"aut","display":"Glahn, Eva Valerie","family":"Glahn"},{"family":"Lederbogen","role":"aut","given":"Florian","display":"Lederbogen, Florian"},{"display":"Deuschle, Michael","role":"aut","given":"Michael","family":"Deuschle"}],"name":{"displayForm":["Maria Gilles, Frank Hentschel, Georgios Paslakis, Valerie Glahn, Florian Lederbogen, Michael Deuschle"]},"physDesc":[{"extent":"2 S."}],"id":{"doi":["10.1097/WNF.0b013e3181f0ec33"],"eki":["1735645524"]},"note":["Gesehen am 15.10.2020"],"relHost":[{"recId":"330078143","origin":[{"publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1976","publisher":"Lippincott Williams & Wilkins ; Ovid","dateIssuedDisp":"1976-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 11.02.03"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Visceral and subcutaneous fat in patients treated with olanzapine a case seriesClinical neuropharmacology","id":{"issn":["1537-162X"],"zdb":["2048796-4"],"eki":["330078143"]},"pubHistory":["1.1976 -"],"part":{"text":"33(2010), 5, Seite 248-249","year":"2010","volume":"33","issue":"5","extent":"2","pages":"248-249"},"language":["eng"],"title":[{"title_sort":"Clinical neuropharmacology","title":"Clinical neuropharmacology"}]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1735645524","origin":[{"dateIssuedDisp":"2010","dateIssuedKey":"2010"}],"title":[{"title":"Visceral and subcutaneous fat in patients treated with olanzapine","subtitle":"a case series","title_sort":"Visceral and subcutaneous fat in patients treated with olanzapine"}],"language":["eng"]} 
SRT |a GILLESMARIVISCERALAN2010